OBJECTIVE: To estimate the risk for spina bifida associated with the common mutation C677T of the MTHFR gene in a country with a relatively low prevalence of NTDs. DESIGN: Case-control study. CASES: 203 living patients affected with spina bifida (173 myelomeningocele and 30 lipomeningocele); controls: 583 subjects (306 young adults and 277 unselected newborns) from northern and central-southern Italy. CASES: three spina bifida centres; young adult controls: DNA banks; newborn controls: regional neonatal screening centres. MAIN OUTCOME MEASURES: Prevalence of the C677T genotypes in cases and controls by place of birth; odds ratios for spina bifida and estimated attributable fraction. RESULTS: The prevalence of T/T, T/C, and C/C genotype was 16.6%, 53.7%, and 29.7% in controls and 25.6%, 43.8%, and 30.6% in cases, respectively. We found no differences between type of defect or place of birth. The odds ratio for spina bifida associated with the T/T genotype v C/C plus T/C was 1.73 (95% CI 1.15, 2.59) and the corresponding attributable fraction was 10.8%. No increased risk was found for heterozygous patients (OR=0.79, 95% CI 0.53-1.18). CONCLUSION: This study, as well as the meta-analysis we updated, shows that homozygosity for the MTHFR C677T mutation is a moderate risk factor in Europe, and even in Italy where there is a relatively low prevalence of spina bifida. The estimated attributable fraction associated with this risk factor explains only a small proportion of cases preventable by periconceptional folic acid supplementation. Thus, other genes involved in folate-homocysteine metabolism, their interaction, and the interaction between genetic and environmental factors should be investigated further.
OBJECTIVE: To estimate the risk for spina bifida associated with the common mutation C677T of the MTHFR gene in a country with a relatively low prevalence of NTDs. DESIGN: Case-control study. CASES: 203 living patients affected with spina bifida (173 myelomeningocele and 30 lipomeningocele); controls: 583 subjects (306 young adults and 277 unselected newborns) from northern and central-southern Italy. CASES: three spina bifida centres; young adult controls: DNA banks; newborn controls: regional neonatal screening centres. MAIN OUTCOME MEASURES: Prevalence of the C677T genotypes in cases and controls by place of birth; odds ratios for spina bifida and estimated attributable fraction. RESULTS: The prevalence of T/T, T/C, and C/C genotype was 16.6%, 53.7%, and 29.7% in controls and 25.6%, 43.8%, and 30.6% in cases, respectively. We found no differences between type of defect or place of birth. The odds ratio for spina bifida associated with the T/T genotype v C/C plus T/C was 1.73 (95% CI 1.15, 2.59) and the corresponding attributable fraction was 10.8%. No increased risk was found for heterozygous patients (OR=0.79, 95% CI 0.53-1.18). CONCLUSION: This study, as well as the meta-analysis we updated, shows that homozygosity for the MTHFR C677T mutation is a moderate risk factor in Europe, and even in Italy where there is a relatively low prevalence of spina bifida. The estimated attributable fraction associated with this risk factor explains only a small proportion of cases preventable by periconceptional folic acid supplementation. Thus, other genes involved in folate-homocysteine metabolism, their interaction, and the interaction between genetic and environmental factors should be investigated further.
Authors: P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel Journal: Nat Genet Date: 1995-05 Impact factor: 38.330
Authors: R P Steegers-Theunissen; G H Boers; F J Trijbels; J D Finkelstein; H J Blom; C M Thomas; G F Borm; M G Wouters; T K Eskes Journal: Metabolism Date: 1994-12 Impact factor: 8.694
Authors: N M van der Put; R P Steegers-Theunissen; P Frosst; F J Trijbels; T K Eskes; L P van den Heuvel; E C Mariman; M den Heyer; R Rozen; H J Blom Journal: Lancet Date: 1995-10-21 Impact factor: 79.321
Authors: Lawrence C Brody; Mary Conley; Christopher Cox; Peadar N Kirke; Mary P McKeever; James L Mills; Anne M Molloy; Valerie B O'Leary; Anne Parle-McDermott; John M Scott; Deborah A Swanson Journal: Am J Hum Genet Date: 2002-10-16 Impact factor: 11.025
Authors: L A Mynett-Johnson; C Keenan; I L Black; W J Livingstone; M Lawler; H M Roche; B White; M J Gibney; P McKeon; O P Smith Journal: Ir J Med Sci Date: 2002 Jan-Mar Impact factor: 1.568
Authors: L Stuppia; V Gatta; O Scarciolla; A Colosimo; P Guanciali-Franchi; G Calabrese; G Palka Journal: J Endocrinol Invest Date: 2003-07 Impact factor: 4.256
Authors: Abee L Boyles; Allen J Wilcox; Jack A Taylor; Klaus Meyer; Ase Fredriksen; Per Magne Ueland; Christian A Drevon; Stein Emil Vollset; Rolv Terje Lie Journal: Am J Med Genet A Date: 2008-02-15 Impact factor: 2.802
Authors: Cecilia Contreras-Cubas; Beatríz E Sánchez-Hernández; Humberto García-Ortiz; Angélica Martínez-Hernández; Francisco Barajas-Olmos; Miguel Cid; Elvia C Mendoza-Caamal; Federico Centeno-Cruz; Gabriela Ortiz-Cruz; José Concepción Jiménez-López; Emilio J Córdova; Eva Gabriela Salas-Bautista; Yolanda Saldaña-Alvarez; Juan Carlos Fernández-López; Osvaldo M Mutchinick; Lorena Orozco Journal: PLoS One Date: 2016-09-20 Impact factor: 3.240